For
immediate release
|
24 April
2024
|
ANGLE plc ("the Company")
NEW COMMERCIAL AGREEMENT WITH LARGE
PHARMA
ANGLE signs agreement to tailor
existing Parsortix-based DNA damage response assay for use in
pharmaceutical R&D
ANGLE plc (AIM:AGL OTCQX:ANPCY), a
world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development
and clinical oncology has signed a supplier agreement with the
global biopharmaceutical company, AstraZeneca PLC, to develop and
validate a methodology leveraging ANGLE's existing DNA damage
response ("DDR") assay for the detection of micronuclei in CTCs as
a measure of DDR.
Under the agreement, ANGLE will
develop a novel methodology for CTC micronuclei detection based on
its existing pKAP1 CTC-based DDR assay, which measures expression
of a key protein in the DNA damage response. Assay development will
take place in ANGLE's laboratories in Guildford, UK, and follows
the Company's development and launch of two highly sensitive and
specific DDR assays in 2023. The 6-month development phase is
worth an initial £150,000 to ANGLE.
ANGLE's DDR assay has the potential
to be used as a repeatable, minimally invasive means to better
understand the DDR pathway to enable development of therapies
capable of targeting tumour-specific DDR dependencies to
preferentially kill cancer cells. The assay may also have the
potential for monitoring treatment response to DDR therapies
administered in combination with other cancer drugs.
ANGLE Chief Executive Officer,
Andrew Newland, commented:
"This is ANGLE's second large pharma
company agreement of 2024 as we look to drive a significant
expansion of the pharma services business. It demonstrates
the importance of CTC analysis and is a validation of ANGLE's
Parsortix system. ANGLE is also working to expand its DDR work with
other large pharma customers and continues to generate significant
new customer interest through its business development
activity."
ANGLE Chief Scientific Officer,
Karen Miller commented:
"We are delighted that our expertise
in CTC assay development continues to make great strides. With the
increasing investigation of DNA damage response / PARP inhibitors,
alone or in combination with chemotherapy or immunotherapy, there
is a need for minimally invasive, robust and repeatable DDR assays.
All the development work continues to add to the menu of assays
owned by ANGLE that we can offer to other customers."
The DDR therapeutics market was
estimated to be valued at US$5.9 billion in 2022 and is projected
to reach US$10.4 billion by 2031 with a CAGR of 6.5%1.
This is expected to be driven by an increase in the use of
combination therapy for the treatment of drug-resistant cancers and
the need for novel targeted medicines for cancer treatment. Most
cancers rely on the DDR pathway to a greater extent than healthy
cells. Treating patients with a DDR inhibitor alongside another
cancer drug helps to maximise DNA damage and selectively kill
cancer cells. This provides a targeted approach to cancer treatment
with the potential to improve patient outcomes across multiple
tumour types.
1.
www.globenewswire.com/en/news-release/2023/07/05/2699419/0/en/DNA-Repair-Drugs-Market-to-Grow-at-6-5-CAGR-Touching-US-10-4-Bn-by-2031-TMR-Study.html
For
further information:
ANGLE plc
|
+44
(0) 1483 343434
|
Andrew Newland, Chief
Executive
Ian Griffiths, Finance
Director
|
|
Berenberg (NOMAD and Corporate Broker)
Toby Flaux, Ciaran Walsh, Milo
Bonser
|
+44
(0) 20 3207 7800
|
FTI
Consulting
Simon Conway, Ciara
Martin
Matthew Ventimiglia (US)
|
+44
(0) 203 727 1000
+1
(212) 850 5624
|
The information contained within
this announcement is deemed by the Company to constitute inside
information as stipulated under the EU Market Abuse
Regulation (596/2014). Upon the publication of this announcement via a regulatory
information service, this information is considered to be in the
public domain.
For Research Use Only. Not for use
in diagnostic procedures.
For Frequently Used Terms, please
see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid
biopsy company with innovative circulating tumour cell (CTC)
solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and
patent protected circulating tumour cell (CTC) harvesting
technology known as the Parsortix® PC1 System enables
complete downstream analysis of the sample including whole cell
imaging and proteomic analysis and full genomic and transcriptomic
molecular analysis.
ANGLE's commercial businesses are
focusing on diagnostic products and clinical services. Diagnostic
products include the Parsortix® system and associated
consumables. The clinical services business is offered through
ANGLE's GCP-compliant laboratories. Services include custom
made assay development and clinical trial testing for
pharma.
Over 90 peer-reviewed publications
have demonstrated the performance of the Parsortix system. For more
information, visit www.angleplc.com